<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175224</url>
  </required_header>
  <id_info>
    <org_study_id>APL-101-01</org_study_id>
    <nct_id>NCT03175224</nct_id>
  </id_info>
  <brief_title>APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors</brief_title>
  <acronym>SPARTA</acronym>
  <official_title>Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apollomics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apollomics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary Phase 1 purpose of this study was to assess overall safety, tolerability and&#xD;
      recommended Phase 2 dose (RP2D) of APL-101.&#xD;
&#xD;
      The Phase 2 portion will assess efficacy of the dose determined in Phase 1 in individuals&#xD;
      with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations; individuals with cancers&#xD;
      associated with c-Met amplifications; individuals with cancers associated with c-Met fusion&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2, multi-center, global, open-label, 2-part study with a Dose Escalation&#xD;
      Segment and Dose and Disease Expansion Cohorts study of APL-101, a c-MET inhibitor, to&#xD;
      determine the recommended Phase 2 dose (RP2D) and dose limiting toxicities for APL-101, and&#xD;
      to obtain preliminary efficacy and target engagement data, in subjects with NSCLC and&#xD;
      advanced malignancies with c-Met dysregulation.&#xD;
&#xD;
      c-MET dysregulation will be determined from historical results by molecular pre-screening&#xD;
      evaluations to determine eligibility of enrollment for both the Dose Escalation Segment&#xD;
      (Phase 1) and Dose and Disease Expansion Cohorts (Phase 2).&#xD;
&#xD;
      Dose escalation will occur until a protocol defined dose limited toxicity (DLT) occurs and a&#xD;
      tentative maximum tolerated dose (MTD) is determined.&#xD;
&#xD;
      Once dose is determined, five cohort groups will be further evaluated:&#xD;
&#xD;
        -  Cohort A-1: NSCLC EXON 14 skip mutation (c-Met naïve, 1L)&#xD;
&#xD;
        -  Cohort A-2: NSCLC EXON 14 skip mutation (c-Met naïve, 2/3L),&#xD;
&#xD;
        -  Cohort B: NSCLC EXON 14 skip mutation (c-Met experienced; progressed on prior c-Met&#xD;
           inhibitor),&#xD;
&#xD;
        -  Cohort C: basket of tumor types (with c-Met high-level amplifications),&#xD;
&#xD;
        -  Cohort D: basket of tumor types (with c-Met fusions)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase 1: Subjects will be assigned to a dose level in the order of study entry. Treatment includes four planned dose levels (100 mg, 200 mg, 300 mg, and 400 mg).&#xD;
Phase 2: Subjects will receive RP2D at 400mg daily dose (200mg BID).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the maximum tolerated dose (MTD) and the incidence of DLTs in Phase 1</measure>
    <time_frame>From the time of informed consent signature through Cycle 1 (28 days) completion</time_frame>
    <description>Adverse events, serious adverse events, and dose limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR = CR + PR) per blinded independent review committee (BIRC) based on RECIST v1.1 (or relevant criteria per tumor type)</measure>
    <time_frame>From time of informed consent signature through completion of treatment (1 cycle = 28 days)</time_frame>
    <description>Anti-tumor activity per RECIST v1.1 or relevant evaluation criteria per tumor type.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median duration of response (DOR) per BIRC.</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>DOR per RECIST v1.1 or relevant evaluation criteria per tumor type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR per investigator assessment based on RECIST v1.1.</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>ORR per RECIST v1.1 or relevant evaluation criteria per tumor type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median DOR per investigator assessment.</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>DOR per RECIST v1.1 or relevant evaluation criteria per tumor type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity by clinical benefit rate (CR + PR + SD ≥ 4 cycles) based on RECIST v1.1 Median time to progression (TTP).</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Benefit rate per RECIST v1.1 or relevant evaluation criteria per tumor type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to progression (TTP).</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>TTP per RECIST v1.1 or relevant evaluation criteria per tumor type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) and overall survival (OS) at 6, 12, 18 and 24 months</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>PFS and OS per RECIST v1.1 or relevant evaluation criteria per tumor type.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">201</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Advanced Cancer</condition>
  <condition>Renal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>NSCLC</condition>
  <condition>Lung Cancer</condition>
  <condition>Brain Tumor</condition>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Single-Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APL-101 Oral Capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APL-101 Oral Capsules</intervention_name>
    <description>Phase 1 Subjects will be assigned to a dose level of APL-101 in the order of study entry. Treatment includes 28-day cycles at four planned dose levels (100mg, 200mg, 300mg and 400mg). Each treatment cycle is administered by daily oral capsules taken every 12 hours.&#xD;
Phase 2 Subjects will be given 400mg daily dose (200mg BID) of APL-101 capsules.</description>
    <arm_group_label>Single-Arm</arm_group_label>
    <other_name>PLB-1001</other_name>
    <other_name>CBI-3103</other_name>
    <other_name>Bozitinib</other_name>
    <other_name>CBT-101</other_name>
    <other_name>Vebreltinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:&#xD;
&#xD;
          -  Able to understand and comply with study procedures, understand the risks involved,&#xD;
             and provide written informed consent.&#xD;
&#xD;
          -  For Phase 1, histologically and / or cytological confirmed unresectable or metastatic&#xD;
             solid malignancy, refractory to standard therapies with no more than three prior lines&#xD;
             of therapy.&#xD;
&#xD;
          -  For Phase 2, five cohorts will be enrolled: Cohort A-1: NSCLC EXON 14 skip mutation&#xD;
             (c-Met naïve) for first line treatment, Cohort A-2: NSCLC EXON 14 skip mutation (c-Met&#xD;
             naïve) pretreated subjects with no more than 3 lines of prior therapy, Cohort B: NSCLC&#xD;
             EXON 14 skip mutation (c-Met experienced; radiographic progression on prior c-Met&#xD;
             inhibitor), Cohort C: basket of tumor types with c-Met high level amplification (NSCLC&#xD;
             EXON 14 skip mutation excluded), Cohort D: basket of tumor type with c-Met fusions.&#xD;
&#xD;
          -  Local/archival result (tissue and/or plasma) of a positive c-Met dysregulation is&#xD;
             required (except in Cohort A-1 in the US).&#xD;
&#xD;
          -  Measurable disease according to RECIST v1.1. (or relevant criteria per tumor type).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
&#xD;
          -  For all prior anticancer treatment, including radiotherapy, chemotherapy or targeted&#xD;
             agents or hormonal therapy, a duration of more than 30 days or 5 half-lives of the&#xD;
             agents used, whichever is shorter, must have elapsed, and any encountered toxicity&#xD;
             must have resolved to levels meeting all the other eligibility criteria prior to the&#xD;
             first dose of study treatment.&#xD;
&#xD;
          -  No planned major surgery within 4 weeks of first dose of APL-101&#xD;
&#xD;
        Major Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to APL-101, excipients of the drug product, or other components of&#xD;
             the study treatment regimen.&#xD;
&#xD;
          -  Known actionable mutation/gene rearrangement of EGFR (except for Cohort C), ALK, ROS1,&#xD;
             RET, NTRK, KRAS, and BRAF.&#xD;
&#xD;
          -  Unstable angina or myocardial infarction within 1 year prior to first dose of APL-101,&#xD;
             symptomatic or unstable arrhythmia requiring medical therapy, history of congenital&#xD;
             prolonged QT syndrome, prolonged QT interval corrected by Fridericia formula (QTcF) at&#xD;
             screening (&gt; 450 msec based on the average of 3 measurements), or concurrent treatment&#xD;
             with a medication that is a known risk for prolonging the QT interval.&#xD;
&#xD;
          -  Unable to swallow orally administered medication whole.&#xD;
&#xD;
          -  Impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
             significantly alter drug absorption (e.g., Crohn's, ulcerative colitis, active&#xD;
             inflammatory bowel disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption&#xD;
             syndrome).&#xD;
&#xD;
          -  Women who are breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Awad, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynn Manlapaz-Espiritu</last_name>
    <phone>16502094055</phone>
    <email>infomed@apollomicsinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Nekhymchuk</last_name>
    <phone>16502094055</phone>
    <email>infomed@apollomicsinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner MD Anderson</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Mozlen</last_name>
      <phone>480-256-5481</phone>
      <email>eileen.molzen@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Jiaxin Niu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela McClure Study Coordinator</last_name>
      <phone>480-342-6076</phone>
      <email>Mcclure.pamela@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mahesh K Seetharam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Sanchez</last_name>
      <email>tisanchez@llu.edu</email>
    </contact>
    <investigator>
      <last_name>Hamid Mirshahidi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiomara Menendez Study Coordinator</last_name>
      <phone>323-865-0212</phone>
      <email>xiomara.menendez@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony El-Khoueiry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle To</last_name>
      <email>Michelle.To@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Jeremy Rudnick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA) Ronald Reagan Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emese Filka</last_name>
      <email>EFilka@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Cloughesy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - CA</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Bacon</last_name>
      <email>Lorena.X.Bacon@kp.org</email>
    </contact>
    <investigator>
      <last_name>Helen Moon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Health</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Foster</last_name>
      <phone>707-521-3836</phone>
      <email>Tracy.Foster@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Ian Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Vallejo</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Desiree Goldstein</last_name>
      <email>Desiree.Goldstein@kp.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer Suga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise DeMaio Study Coordinator</last_name>
      <email>Denise.A.DeMaio@ChristianaCare.org</email>
    </contact>
    <investigator>
      <last_name>Michael Guarino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - South</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Cowan</last_name>
      <email>pcowan@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Anjan Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Georgiou Study Coordinator</last_name>
      <phone>904-953-8667</phone>
      <email>georgiou.Andrea@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kabir Mody, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Fogg-Smith, MS</last_name>
      <phone>407-303-7325</phone>
      <email>Stacy.Fogg-Smith@AdventHealth.com</email>
    </contact>
    <investigator>
      <last_name>Mark Socinski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - North</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dinah Welsh-Barnes</last_name>
      <email>dibarnes@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Vijay Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Wright</last_name>
      <email>pwright@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Viralkumar Bhanderi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Hunter</last_name>
      <email>jeff.hunter@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Ben Creelan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Bar-nur</last_name>
      <email>jbar-nur@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Eric Harris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Scuderi</last_name>
      <email>Heather.scuderi@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zara Necesario</last_name>
      <email>Zara.Necesario@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Kashif Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Yoon</last_name>
      <phone>617-975-7449</phone>
      <email>pyoon@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Costa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Xiong</last_name>
      <email>michellex_xiong@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Awad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Birgin Study Coordinator</last_name>
      <phone>507-266-7093</phone>
      <email>Birgin.ann@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Sani H Kizilbash, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Institute - Frauenshuh Cancer Center</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grant Gunderson Program Manager</last_name>
      <phone>952-993-1555</phone>
      <email>grant.gunderson@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Rachel Lerner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Health</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie May</last_name>
      <phone>816-276-4619</phone>
      <email>Stephanie.May@hcamidwest.com</email>
    </contact>
    <investigator>
      <last_name>Syed Karim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Fogal</last_name>
      <phone>314-362-1518</phone>
      <email>clfogal@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Siddhartha Devarakonda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allie Mayer</last_name>
      <phone>919-966-4091</phone>
      <email>allie.mayer@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Claire Dees, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Naska</last_name>
      <email>naskat@ccf.org</email>
    </contact>
    <investigator>
      <last_name>David Peereboom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University (OSU)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgan Hill</last_name>
      <email>Morgan.Hill@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Erin Bertino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kettering Health Network</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Keeton Study Coordinator</last_name>
      <email>kelly.keeton@ketteringhealth.org</email>
    </contact>
    <investigator>
      <last_name>Emily Franks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanda Neidig</last_name>
      <email>wneidig@pennstatehealth.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Francis Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Adams Clinical Research Coordinator</last_name>
      <phone>864-603-6219</phone>
      <email>amy_adams@bshi.org</email>
    </contact>
    <investigator>
      <last_name>Robert Siegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon and HCA Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Callaway</last_name>
      <phone>615-524-7283</phone>
      <email>brittany.callaway@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>David Spigel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Don &amp; Sybil Harrington Cancer Center</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Blades</last_name>
      <email>Nancy.Blades@bsahs.org</email>
    </contact>
    <investigator>
      <last_name>Anita Ravipati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arun Athithan</last_name>
      <email>Arun.athithan@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Sona Puri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MultiCare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Macon Clinical Research Coordinator</last_name>
      <phone>253-403-0791</phone>
      <email>smmacon@multicare.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer Slim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Cancer Institute</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia McEwuen Study Coordinator, BSN</last_name>
      <phone>304-293-1683</phone>
      <email>smcewuen@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Mohammed Almubarak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Warnell Study Coordinator</last_name>
      <phone>608-265-0811</phone>
      <email>brittany.warnell@wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Burkard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Richards</last_name>
      <email>alison.richards@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Chris Karapetis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>Albury</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Shaw</last_name>
      <email>cshaw@bordermedonc.com.au</email>
    </contact>
    <investigator>
      <last_name>Criad Underhill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital Melbourne</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Ranieri</last_name>
      <email>Nadia.ranieri@svha.org.au</email>
    </contact>
    <investigator>
      <last_name>Melissa Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Lind</last_name>
      <email>monica.lind@health.wa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Kevin Jasas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calvary Central Districts Hospita</name>
      <address>
        <city>North Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Smith</last_name>
      <email>sophie.smith@calvarycare.org.au</email>
    </contact>
    <investigator>
      <last_name>Vineet Kwatra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lady Davis Institute for Medical Research Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daria Krutauz</last_name>
      <phone>514-340-8222 ext: 24301</phone>
      <email>daria.krutauz.ccomtl@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Jason Agulnik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Forrest</last_name>
      <email>Dominique.Forrest@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Siu-Chung (Quincy) Chu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center - Research Institute</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Raby</last_name>
      <email>nicola.raby@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Scott Owen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Sawczak</last_name>
      <email>Maggie.Sawczak@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Natasha Leighl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robyn Guarino</last_name>
      <email>rguarino@cancercare.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Shantanu Banerji</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospita</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Ahlskog</last_name>
      <email>kerstin.ahlskog@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Aija Knuuttila</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjo Koivisto</last_name>
      <email>marjo.koivisto@pshp.fi</email>
    </contact>
    <investigator>
      <last_name>Jaarko Ahvonen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest - Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amellie Crie</last_name>
      <email>amelie.crie@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles Robinet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Wasielewski</last_name>
      <email>eric.wasielewski@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Alexis Cortot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryem Lahbib</last_name>
      <email>Maryem.LAHBIB@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Maurice Perol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat - Claude Bernard - AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celine Namour</last_name>
      <email>celine.namour@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Gerard Zalcman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurène Masson</last_name>
      <email>Laurene.MASSON@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Herve Lena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannane Hamidi</last_name>
      <email>Hannane.HAMIDI@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>David Planchard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szent Borbala Korhaz</name>
      <address>
        <city>Tatabanya</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaborne Szekeres</last_name>
      <email>modiga88@gmail.com; modiga@gmail.hu</email>
    </contact>
    <investigator>
      <last_name>Csaba Böcskei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco - Presidio Ospedaliero G. Rodolico</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Attina</last_name>
      <email>attinasonia.sc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Manuela Lo Porto Soto Parra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia Pagan</last_name>
      <phone>+39 0543 739 423</phone>
      <email>flavia.pagan@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Angelo Delmonte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara Fugazza</last_name>
      <email>fugazza.clara@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Vanesa Gregorc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PanOncology Trials, LLC</name>
      <address>
        <city>Rio Piedras</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Ramirez</last_name>
      <phone>787-607-3336</phone>
      <email>virginia.ramirez@panoncologytrials.com</email>
    </contact>
    <investigator>
      <last_name>Marcia Cruz-Correa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Clinical Oncological Dispensary</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarina Anastasia</last_name>
      <email>sharinaay@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Marina Nechaeva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Medical Institution Euromedservice</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandr Krestianinov</last_name>
      <email>Krestalexserg@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Konstantin Penkov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg Clinical Research Center of Specialized Types of Medical Care (Oncology)</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariia Gutina</last_name>
      <email>veselova.oncocentr@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Fedor Moiseenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ogarev Mordovia State University</name>
      <address>
        <city>Saransk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Artem Ivashin</last_name>
      <email>a.iwashin2017@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Pavel Skopin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JSC Current Medical Technologies</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana Kryukova</last_name>
      <email>tretnikovasvetlana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Svetlana Odintsova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Volgograd Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marakova Lyubov</last_name>
      <email>makarova.lyubov.vlg@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nadezhda Kovalenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiling Chua</last_name>
      <phone>chua.shi.ling@nccs.com.sg</phone>
      <email>chua.shi.ling@nccs.com.sg</email>
    </contact>
    <investigator>
      <last_name>Geet Yi Gillianne Lai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncocare Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vera Chen</last_name>
      <email>Vera_Chen@oncocare.sg ; veraqxchen@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Swan Swan Leong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Jia Min Ng</last_name>
      <email>Jamie_JM_NG@ttsh.com.sg</email>
    </contact>
    <investigator>
      <last_name>Puey ling Chia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Saldaña</last_name>
      <email>ssaldana@igtp.cat</email>
    </contact>
    <investigator>
      <last_name>Enric Carcereny Costa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ainara Arcocha</last_name>
      <email>AARCOCHA@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Noemi Reguart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Galtes</last_name>
      <email>sgaltescruces@parcdesalutmar.cat</email>
    </contact>
    <investigator>
      <last_name>Alvaro Taus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia - L'Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Begoña Hernández Coll</last_name>
      <email>bhernandezc@idibell.cat</email>
    </contact>
    <investigator>
      <last_name>Ernest Nadal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Villar Rodriguez</last_name>
      <email>crisrvillar83.hgugm@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Calles Blanco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Rodriguez</last_name>
      <email>rrodriguez@h12o.es</email>
    </contact>
    <investigator>
      <last_name>Santiago Ponce</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Cerdeira</last_name>
      <phone>+34 91 191 7418</phone>
      <email>scerdeira.hpth@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Mariano Provencio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Ruiz</last_name>
      <email>elena.ruizal@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Pilar Garrido</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Uriol Egido</last_name>
      <email>uriol.esther@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Emilio Esteban</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>San Sebastián</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Diez</last_name>
      <email>maria.diezzubizarreta@osakidetza.eus</email>
    </contact>
    <investigator>
      <last_name>Alfredo Paredes Lario</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esperanza Munoz</last_name>
      <email>espe.m.garcia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Reyes Bernabe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amparo Ortiz</last_name>
      <email>datamanager6@fincivo.org</email>
    </contact>
    <investigator>
      <last_name>Angel Guerrero Zotano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University - Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Ping Chi</last_name>
      <email>20232@s.tmu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Kang-Yun Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chi-Mei Hospital - Liouying Branch</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Chen</last_name>
      <email>hospital77649@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chao-Jung Tsao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Pei Lin</last_name>
      <email>906329@ntuh.gov.tw</email>
    </contact>
    <investigator>
      <last_name>James Chih-Hsin Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsiao-Ling Liu</last_name>
      <email>acis70@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Han-Pin Kuo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital (CGMHLK)</name>
      <address>
        <city>Taoyuan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Shiou Hsiao</last_name>
      <email>ifyn1011@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Cheng-Ta Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Hematology Center of Municipal Non-Profit Enterprise &quot;City Clinical Hospital #4&quot; DCC</name>
      <address>
        <city>Dnipropetrovs'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Igor Bondarenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Communal Non-commercial Enterprise of Kharkiv Regional Council Regional Clinical Specialized Dispensary of Radiation Protection of Population, Department of Surger</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kateryna Kotelevets</last_name>
      <email>kotelevets15@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maryna Neffa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Institution V.T.Zaitsev Institute of General and Urgent Surgery of National Academy of Medical Sciences of Ukraine, Department of Purulent Surgery</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmytro Piliuhin</last_name>
      <email>cisplatin50@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Oleksandr Dudnichenko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyiv Municipal Clinical Oncology Center</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olga Ponomarova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Martinez</last_name>
      <email>m.martinez@nhs.net</email>
    </contact>
    <investigator>
      <last_name>David Pinato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Wooley</last_name>
      <email>sharon.woolley@christie.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Colin Lindsay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Surrey</name>
      <address>
        <city>Surrey Quays</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anna Minchom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
  </removed_countries>
  <link>
    <url>https://www.apollomicsinc.com</url>
    <description>Apollomics, Inc. website</description>
  </link>
  <link>
    <url>http://spartacancertrial.com</url>
    <description>SPARTA Study website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>August 22, 2021</last_update_submitted>
  <last_update_submitted_qc>August 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Relapsed Solid Tumor</keyword>
  <keyword>Recurrent Solid Tumor</keyword>
  <keyword>cMet exon 14 skipping</keyword>
  <keyword>cMet fusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

